Twenty-five years ago, Novartis pioneered a paradigm shift in cancer care with the introduction of the first tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), transforming it from a deadly disease into a chronic condition for most patients. This breakthrough helped lay the foundation for targeted therapies in oncology and continues to shape the future of CML treatment today.

The creation of a 700,000-square-foot flagship manufacturing hub marks the continuation of our investment in the US, enabling us to more reliably reach patients across the country.

As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.